BioCentury | May 26, 2016
Product R&D

H is for cancer

...light and dark blue) , which respectively contained heavy and light chain complementarity determining regions (HCDR1-3...
BioCentury | Jan 20, 2014
Company News

XTL, Weizmann Institute of Science deal

...and Development Co. Ltd., the institute's technology transfer company, granted XTL exclusive, worldwide rights to hCDR1...
...SRI), according to XTL. The company believes it has a greater likelihood to successfully develop hCDR1...
BioCentury | Jan 28, 2008
Strategy

Teva's biosimilars play

...the company has been looking to augment its biologics capabilities. The company's biologics pipeline includes edratide...
BioCentury | Sep 24, 2007
Clinical News

Edratide: Phase II data

...the study's secondary endpoints have been completed. Teva Pharmaceutical Industries Ltd. (TEVA), Jerusalem, Israel Product: Edratide...
BioCentury | Sep 20, 2007
Clinical News

Teva's edratide misses lupus endpoint

...TEVA said edratide (TV-4710) missed the primary endpoint of a significant reduction in lupus disease activity...
BioCentury | May 15, 2006
Product Development

SLE pipeline

...B lymphocyte stimulator protein) MAb Ph II (start Ph III by YE) GlaxoSmithKline Teva Edratide (TV-4710...
BioCentury | May 5, 2003
Company News

CyDex Inc., Teva deal

...granted TEVA global rights to use CyDex's Captisol drug delivery technology for use with TEVA's TV-4710...
Items per page:
1 - 7 of 7